Jobbeschreibung
„Research for a life without cancer“ is our mission at the German Cancer Research Center. We investigate how cancer develops, identify cancer risk factors and look for new cancer prevention strategies. We develop new methods with which tumors can be diagnosed more precisely and cancer patients can be treated more successfully. Every contribution counts – whether in research, administration or infrastructure. This is what makes our daily work so meaningful and exciting.
The German Cancer Research Center (DKFZ) is seeking for the National Center for Tumor Diseases (NCT) Heidelberg for as soon as possible a
Postdoctoral Researcher
Reference number: 2025-0096
- Heidelberg
- Full-time
- Translational Medical Oncology at DKFZ and NCT Heidelberg
The Section of Translational Cancer Epigenomics headed by Dr. Daniel Lipka is part of the Division of Translational Medical Oncology at the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelberg. We are a dynamic international group of scientists working together with renowned national and international collaboration partners. In our group, we combine basic and translational research to discover and implement novel diagnostic and therapeutic approaches to malignant diseases. The main focus is on the analysis of epigenomic alterations occurring in premalignant and malignant cells as compared to their normal counterparts in order to understand how aberrant epigenetic programming impacts on tumor initiation and progression.
Your Tasks
The postdoctoral researcher will work as part of an interdisciplinary team of scientists investigating the molecular defects elicited by oncogenic IDH1 mutations. IDH1 mutations are found in several malignancies and result in the production of the oncometabolite D-2- hydroxyglutarate (D2HG). D2HG was shown to alter epigenetic regulation and to support tumorigenesis. However, the prescise molecular mechanisms underlying the tumorigenic effects of mutant IDH1 remain elusive. The successful candidate will use established in vitro and in vivo models of mutant IDH1 to assess the early and cell type-specific effects of mutant IDH1 on genetic and epigenetic integrity and the resulting transcriptional aberrations that provide a fertile soil for malignant transformation. These studies will involve the use of cutting-edge technologies (EpiCyTOF, metabolomics, ACT-, ATAC-, RNA-seq, nanopore sequencing, CRISPRi and CRISPRa) to assess the molecular aberrations involved and their consequences on cell function and phenotype. Ultimately, these results might lead to the development of novel treatment options beyond inhibition of the mutant enzyme for patients with IDH1-mutant malignancies.
Your Profile
We are looking for a highly motivated and ambitious postdoctoral scientist who is committed to cancer research at the crossroads of experimental hematology, epigenomics and metabolism. The candidate should be able to work independently but should also have excellent teamwork skills. Applicants must hold a Ph.D. in biology, biochemistry, biotechnology, or a related field, and have published previously in international peerreviewed journals. Expertise in molecular and cellular biology, with a specific focus on experimental hematology and/or epigenomics is advantageous. Profound knowledge of cancer biology, strong communication skills, and excellent written and oral command of English are required.
The application should include a curriculum vitae, a motivation letter, degree certificates, the expected availability date, a complete list of publications, and the names and contact information of at least two references.
We Offer
- Excellent framework conditions: state-of-the-art equipment and opportunities for international networking at the highest level
- Remuneration according to TV-L incl. occupational pension plan and capital-forming payments
- 30 days of vacation per year
- Flexible working hours
- Possibility of part-time work
- Family-friendly working environment
- Sustainable travel to work: subsidized Germany job ticket
- Our Corporate Health Management Program offers a holistic approach to your well-being
- Develop your full potential: access to the DKFZ International Postdoc Program and DKFZ Career Service with targeted offers for your personal development to further develop your talents
Contact:
Dr. Daniel Lipka
Phone: +49 6221 42-1603
The position is initially limited to 2 years with the possibility of prolongation.
Are you interested?
Then become part of the DKFZ and join us in contributing to a life without cancer!
Apply now
We are convinced that an innovative research and working environment thrives on the diversity of its employees. Therefore, we welcome applications from talented people, regardless of gender, cultural background, nationality, ethnicity, sexual identity, physical ability, religion and age. People with severe disabilities are given preference if they have the same aptitude.
Notice: We are subject to the regulations of the Infection Protection Act (IfSG). Therefore, all our employees must provide proof of immunity against measles.
Share this job!
Deutsches Krebsforschungszentrum | Im Neuenheimer Feld 280 | 69120 Heidelberg | www.dkfz.de
